Redefining what's possible in autoimmune disease
Artiva is developing the first deep B-cell depleting therapy of any modality to reach Phase 3 in rheumatoid arthritis. We are also conducting a Phase 2a study in multiple autoimmune diseases.
AlloNK®: Bringing Deep B-Cell Depletion to Autoimmune Disease
AlloNK is an investigational, allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy, administered in combination with rituximab to target B cells. The goal is B-cell Reset™: deeply depleting disease-driving B cells and allowing a healthier B-cell population to reconstitute over time. This approach is intended to achieve deep B-cell depletion without engineering or redirecting T cells.
Across multiple autoimmune diseases, initial data have demonstrated that AlloNK drove deep and uniform B-cell depletion, reconstitution with a predominance of naïve and transitional B cells and clinical improvements across multiple disease measures. These early results appear in line with the clinical activity reported with autologous CAR T approaches, and patients continue to be followed to understand durability and the potential role of repeat treatment. No CRS or ICANS was observed in the autoimmune safety dataset as of April 3, 2026, supporting continued development in outpatient and community rheumatology settings.
Initiating a Phase 3 Trial in Refractory RA
Many people with rheumatoid arthritis continue to have active disease after an inadequate response to multiple biologic or targeted therapies. Artiva is advancing AlloNK® for refractory rheumatoid arthritis and is initiating a Phase 3 registrational trial in the second half of 2026.
AlloNK is an investigational therapy and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
The clinical data for AlloNK are based on separate studies and include data from Artiva’s company-sponsored Phase 2a basket trial and an investigator-initiated basket trial. No head-to-head trial has evaluated AlloNK against the other therapies discussed on this website. Differences in trial design, patient populations and product candidates limit cross-trial comparisons.